Completed
Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SILVER Study
What is being tested
Data Collection
Who is being recruted
Cardiovascular Diseases+6
+ Heart Diseases
+ Cardiomegaly
Over 50 Years
+24 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 2
Interventional
Study Start: August 2001
Summary
Principal SponsorSynvista Therapeutics, Inc
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Study start date: August 1, 2001
Actual date on which the first participant was enrolled.The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal study in patients with left ventricular hypertrophy. Eligible patients will be randomized to double-blind treatment once daily for 6 months with oral ALT-711 (210 mg) or placebo.
Official TitleSystolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SILVER Study
Principal SponsorSynvista Therapeutics, Inc
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
180 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 50 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Cardiovascular DiseasesHeart DiseasesCardiomegalyHypertensionHypertrophyPathological Conditions, Signs and SymptomsVascular DiseasesHypertrophy, Left VentricularPathological Conditions, Anatomical
Criteria
5 inclusion criteria required to participate
Men or women at least 50 years of age.
Patients with left ventricular hypertrophy (LVH) as determined by limited echocardiography for LVH (i.e., wall thickness > 1.2 cm).
Patient can complete an informed consent.
Screening diagnosis of isolated systolic hypertension, defined as systolic blood pressure >150 mm Hg and diastolic blood pressure <90 mm Hg (office blood pressure measurements) and systolic blood pressure >140 mm Hg (measured by 24-hour ambulatory blood pressure monitoring-mean daytime values).
Show More Criteria
19 exclusion criteria prevent from participating
Hb A1c > 9%.
Patient <50 years of age.
Patients on antihypertensive therapy with changes in dose in the last 1 month prior to the entry into the study.
Serum creatinine > 1.7mg/dL.
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers